Clinical utility of CEA, CA 19-9, and CA 72-4 in the follow-up of patients with resectable gastric cancer
- 1 January 2001
- journal article
- Published by Elsevier in The American Journal of Surgery
- Vol. 181 (1) , 16-19
- https://doi.org/10.1016/s0002-9610(00)00549-3
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Adjuvant therapy for gastric carcinoma patients in the past 15 yearsCancer, 1999
- Phase II Study of Combined Administration of 5-Fluorouracil, Epirubicin and Mitomycin-C by Hepatic Artery Infusion in Patients with Liver Metastases of Gastric CancerOncology, 1999
- Prognostic Significance of CEA, CA 19-9 and CA 72-4 Preoperative Serum Levels in Gastric CarcinomaOncology, 1999
- Improved mortality rate of gastric carcinoma patients with peritoneal carcinomatosis treated with intraperitoneal hyperthermic chemoperfusion combined with surgeryCancer, 1997
- Comparison of serum CA 72-4 and CA 19-9 levels in gastric cancer patients and correlation with recurrenceThe American Journal of Surgery, 1995
- Comparative analysis of cancer-associated antigen CA-195, CA19-9 and carcinoembryonic antigen in diagnosis, follow-up and monitoring of response to chemotherapy in patients with gastrointestinal cancerZeitschrift für Krebsforschung und Klinische Onkologie, 1991
- Comparison of CA 72–4 with CA 19–9 and Carcinoembryonic Antigen in the Serodiagnostics of Gastrointestinal MalignanciesScandinavian Journal of Gastroenterology, 1989